Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer
Significant PFS Improvement:
Imlunestrant, an oral selective estrogen receptor degrader (SERD), significantly improved progression-free survival (PFS) in patients with ER+, HER2- advanced breast cancer, both as monotherapy and in combination with Verzenio (abemaciclib)135.
Monotherapy Benefits:
Imlunestrant reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations1.
Combination Therapy Benefits:
The combination of imlunestrant and Verzenio reduced the risk of progression or death by 43% compared to imlunestrant alone in all patients, regardless of ESR1 mutation status15.
Clinical Trial Results:
The EMBER-3 study demonstrated these benefits, with median PFS of 9.4 months for the imlunestrant-Verzenio combination versus 5.5 months for imlunestrant alone1.
Potential Therapeutic Shift:
The results suggest a potential shift in therapy options for CDK4/6 pre-treated ER+, HER2- advanced breast cancer patients, who currently have limited treatment options1.
Safety Profile:
The combination therapy showed a safety profile consistent with the known safety profile of fulvestrant in combination with abemaciclib, with mostly low-grade adverse events1.
Sources:
1. https://investor.lilly.com/news-releases/news-release-details/lillys-imlunestrant-oral-serd-significantly-improved-progression
3. https://endpts.com/sabcs24-lillys-oral-serd-makes-strides-in-breast-cancer-with-phase-3-data/